Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 6:20 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 217–240 of 768 matching trials from the live ClinicalTrials.gov search.
Conditions
Adult Acute Myeloid Leukemia in Remission, Childhood Acute Myeloid Leukemia in Remission
Interventions
Cytarabine, Laboratory Biomarker Analysis, Peripheral Blood Stem Cell Transplantation, Therapeutic Allogeneic Lymphocytes, G-CSF mobilized peripheral blood cells
Drug · Other · Procedure + 1 more
Lead sponsor
University of Southern California
Other
Eligibility
Up to 59 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Los Angeles, California
Conditions
Acute Myeloid Leukemia
Interventions
oral azacitidine (CC-486)
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
1
States / cities
New Haven, Connecticut
Conditions
Leukemia, Lymphoma, Psychosocial Effects of Cancer and Its Treatment, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
complementary or alternative medicine procedure, management of therapy complications, psychosocial assessment and care
Procedure
Lead sponsor
Leap of Faith Technologies
Industry
Eligibility
10 Years to 15 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
1
States / cities
Crystal Lake, Illinois
Conditions
Mantle Cell Lymphoma
Interventions
Autologous Hematopoietic Stem Cell Transplantation, Biospecimen Collection, Bone Marrow Aspirate, Bone Marrow Biopsy, Computed Tomography, Positron Emission Tomography, Rituximab, Rituximab and Hyaluronidase Human
Procedure · Biological
Lead sponsor
ECOG-ACRIN Cancer Research Group
Network
Eligibility
18 Years to 70 Years
Enrollment
689 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
374
States / cities
Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 236 more
Conditions
Urticaria
Interventions
Vitamin D (4,000 IU/day), Vitamin D (400 IU/day), Omalizumab
Dietary Supplement · Drug
Lead sponsor
Selina Gierer, D.O.
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Kansas City, Kansas
Conditions
Crohn's Disease in Remission
Interventions
Low Sulfur Diet, Usual Diet
Other
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Ann Arbor, Michigan
Conditions
Breast Cancer, HER2-positive Breast Cancer, Breast Cancer Stage IV
Interventions
Personalis NeXT Personal, Natera Signatera, fam-trastuzumab deruxtecan-nxki (T-DXd), pertuzumab, called T-DXd+P
Diagnostic Test · Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Conditions
Chronic Myelomonocytic Leukemia-2, Myelodysplastic Syndrome, Myeloproliferative Neoplasm, Untreated Adult Acute Myeloid Leukemia
Interventions
Cytarabine, Decitabine, Laboratory Biomarker Analysis
Drug · Other
Lead sponsor
University of Washington
Other
Eligibility
60 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
9
States / cities
Bozeman, Montana • Kennewick, Washington • Kirkland, Washington + 6 more
Conditions
Type 2 Diabetes Mellitus
Interventions
Exendin9
Drug
Lead sponsor
Blandine Laferrere
Other
Eligibility
18 Years to 65 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
New York, New York
Conditions
Crohn's Disease
Interventions
Rifaximin EIR, Placebo
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years and older
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
78
States / cities
Huntsville, Alabama • Tucson, Arizona • Sherwood, Arkansas + 68 more
Conditions
Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases
Interventions
anti-thymocyte globulin, cyclophosphamide, cyclosporine, fludarabine phosphate, methylprednisolone, UV light therapy, allogeneic bone marrow transplantation, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years to 120 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
1
States / cities
Cleveland, Ohio
Conditions
Crohn's Disease
Interventions
Enhanced Treatment Algorithm, Conventional Step-care Algorithm
Other
Lead sponsor
Alimentiv Inc.
Other
Eligibility
18 Years and older
Enrollment
1,095 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
5
States / cities
Washington D.C., District of Columbia • Urbana, Illinois • Shreveport, Louisiana + 2 more
Terminated Phase 2 Interventional Accepts healthy volunteers

Vedolizumab Induction May Prevent Celiac Enteritis

NCT02929316
Conditions
Celiac Disease
Interventions
Vedolizumab
Drug
Lead sponsor
AGA Clinical Research Associates, LLC
Other
Eligibility
18 Years to 75 Years
Enrollment
1 participant
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
2
States / cities
Egg Harbor, New Jersey
Conditions
Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases, Sarcoma
Interventions
filgrastim, busulfan, cyclophosphamide, cyclosporine, etoposide, methotrexate, allogeneic bone marrow transplantation, radiation therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
Up to 24 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Portland, Oregon
Conditions
Childhood Acute Lymphoblastic Leukemia in Remission
Interventions
Compliance Monitoring, Laboratory Biomarker Analysis, Mercaptopurine, Methotrexate, Questionnaire Administration, Study of Socioeconomic and Demographic Variables
Behavioral · Other · Drug
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 21 Years
Enrollment
720 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2020
U.S. locations
124
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Downey, California + 105 more
Conditions
Neuroblastoma
Interventions
3F8 and 13-cis-retinoic acid
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Months and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
1
States / cities
New York, New York
Conditions
Leukemia, Lymphoma
Interventions
biologic sample preservation procedure
Other
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
0 Years to 120 Years
Enrollment
1,873 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2014
U.S. locations
214
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Aurora, Colorado + 156 more
Conditions
Leukemia
Interventions
filgrastim, asparaginase, cytarabine, daunorubicin hydrochloride, melphalan, thioguanine, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 21 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2007
U.S. locations
19
States / cities
Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 15 more
Conditions
Graft Versus Host Disease, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases, Secondary Myelofibrosis
Interventions
anti-thymocyte globulin, busulfan, cyclophosphamide, mycophenolate mofetil, tacrolimus, polymerase chain reaction, polymorphism analysis, flow cytometry, laboratory biomarker analysis, pharmacogenomic studies, pharmacological study, allogeneic bone marrow transplantation, allogeneic hematopoietic stem cell transplantation, peripheral blood stem cell transplantation
Biological · Drug · Genetic + 2 more
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years to 65 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Omaha, Nebraska
Conditions
Leukemia
Interventions
cyclophosphamide, methotrexate, allogeneic bone marrow transplantation, iodine I 131 monoclonal antibody BC8, radiation therapy
Drug · Procedure · Radiation
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
2 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2001
U.S. locations
2
States / cities
Seattle, Washington
Conditions
Depression
Interventions
Interpersonal Psychotherapy, Fluoxetine
Behavioral · Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
20 Years to 60 Years · Female only
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 2001
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Conditions
Childhood Acute Lymphoblastic Leukemia in Remission, Childhood Acute Myeloid Leukemia in Remission, Childhood Chronic Myelogenous Leukemia, Childhood Myelodysplastic Syndromes, Chronic Phase Chronic Myelogenous Leukemia, de Novo Myelodysplastic Syndromes, Juvenile Myelomonocytic Leukemia, Previously Treated Myelodysplastic Syndromes, Recurrent Childhood Acute Lymphoblastic Leukemia, Secondary Myelodysplastic Syndromes
Interventions
allogeneic bone marrow transplantation, laboratory biomarker analysis, filgrastim
Procedure · Other · Biological
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 21 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2022
U.S. locations
21
States / cities
Arcadia, California • San Francisco, California • Aurora, Colorado + 17 more
Terminated Phase 2 Interventional Results available

KAP for Depression in Abstinent Opioid Users

NCT05193318
Conditions
Opioid Use Disorder, Severe, in Sustained Remission, Opioid Use Disorder, Severe, in Early Remission, Major Depressive Disorder
Interventions
Ketamine-assisted psychotherapy
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 64 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Charleston, South Carolina
Conditions
Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
Interventions
Irradiated haploidentical allogeneic lymphocytes, total-body irradiation
Biological · Radiation
Lead sponsor
University of Medicine and Dentistry of New Jersey
Other
Eligibility
13 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
New Brunswick, New Jersey